Status:
UNKNOWN
Plasmablast Detection From IgG4-Related Disease Patients
Lead Sponsor:
Meir Medical Center
Conditions:
IgG4-related Disease
Eligibility:
All Genders
18+ years
Brief Summary
IgG4-related disease (IgG4-RD) is an immune-mediated, fibro-inflammatory disease that leads to tissue damage, organ dysfunction and, if untreated, to organ failure. The disease can affect almost any a...
Detailed Description
IgG4-related disease (IgG4-RD) is an immune-mediated, fibro-inflammatory disease that leads to tissue damage, organ dysfunction and, if untreated, to organ failure. The disease can affect almost any a...
Eligibility Criteria
Inclusion
- Patients that obtaining their written consent.
- Patients above the age of 18 and referred to the Rheumatology clinic or Internal Medicine E Department at the Meir Medical Center for investigation or treatment of IgG4-RD will be candidates to participate in the study.
- Patients at their primary diagnosis or follow up will be eligible for this study.
Exclusion
- Patient that not diagnosed before with IgG4.
- patients that does not referred to the Rheumatology clinic or Internal Medicine E Department at the Meir Medical Center.
Key Trial Info
Start Date :
April 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 1 2019
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT03466970
Start Date
April 1 2018
End Date
April 1 2019
Last Update
March 16 2018
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Yael Eizikovits
Kfar Saba, Israel, 44281
2
Meir health center
Kfar Saba, Israel